ProPhase Labs Inc (PRPH, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. ProPhase Labs Inc is a manufacturer and distributor of homeopathic and health products. It is also engaged in the research & development of potential over-the-counter drug, natural health products, supplements, personal care & cosmeceutical products. ProPhase Labs Inc has a market cap of $32.830 million; its shares were traded at around $2.95 with a P/E ratio of 1.17 and P/S ratio of 2.14.
For the last quarter ProPhase Labs Inc reported a revenue of $4.15 million, compared with the revenue of $17.58 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $9.87 million, a decrease of 53% from the previous year. For the last five years ProPhase Labs Inc had an average revenue decline of 12.6% a year.
The reported diluted earnings per share was $2.67 for the year, compared with the loss per share of $0.03 in the previous year. The ProPhase Labs Inc had an operating margin of -40.44%, compared with the operating margin of -12.64% a year before. The 10-year historical median operating margin of ProPhase Labs Inc is -16.54%. The profitability rank of the company is 3 (out of 10).
At the end of the fiscal year, ProPhase Labs Inc has the cash and cash equivalents of $3.17 million, compared with $0.44 million in the previous year. The company had no long term debt. ProPhase Labs Inc has a financial strength rank of 8 (out of 10).
At the current stock price of $2.95, ProPhase Labs Inc is traded at 63.9% premium to its historical median P/S valuation band of $1.80. The P/S ratio of the stock is 2.14, while the historical median P/S ratio is 1.31. The stock gained 47.81% during the past 12 months.
For the complete 20-year historical financial data of PRPH, click here.
